Skip to content

Ensuring that we work ethically and with integrity is incredibly important to us. Our commitment to being a trusted supplier and partner extends throughout our activities, from our relationships with business partners, through the quality of the medicines we supply, to ensuring that health professionals and patients understand how to use our medicines safely and effectively.

We recognise that our reputation as a company is developed or diminished by the actions of each individual working here and so we ensure that our employees are aware of their responsibilities to abide by both the Napp Code of Business Ethics and the Association of the British Pharmaceutical Industry (ABPI) Code of Practice.

The Napp Code of Business Ethics sets out guiding principles that we live by in relation to our interactions with partners, suppliers, customers and each other. We expect all our employees, and those with whom we do business, to abide by these principles. You can read our Code of Business Ethics here.

The ABPI Code of Practice governs our activities in relation to the promotion of our medicines. Working in healthcare carries a great deal of responsibility to ensure that we market our medicines ethically and professionally, and we endeavor to follow the ABPI Code of Practice in all our activities. You can read more about the ABPI Code of Practice here.

Quality and safety of our medicines

The quality and safety of our medicines is of paramount importance to us. Napp’s medicines are manufactured and supplied by Bard Pharmaceuticals Limited and other partners.

Our commitment to safety continues after the point of prescription. Ongoing safety monitoring for our medicines is vitally important, and we comply with all the relevant requirements to ensure that we continue to track the safety of our medicines during their use by patients. We encourage healthcare professionals and patients to report any unwanted effects of our medicines direct to our Drug Safety Team and through the Medicine and Healthcare Products Regulatory Agency (MHRA) yellow card reporting scheme as this helps us to identify any potential problems as quickly as possible.

Carbon Reduction Plan 2024

Napp Pharmaceutical Holdings Limited and its subsidiaries* aims to achieve net-zero Scope 1, 2 and 3 emissions by 2050 at the latest from a 2022 base year. Our reduction plan is presented in response to the recent Procurement Policy Note (PPN) 06/21 and provides transparency and demonstrates our progress towards building a robust carbon reduction programme. To view Carbon Reduction Plan 2024 click here.

*Napp Pharmaceutical Holdings Limited subsidiaries for this Plan comprise Napp Pharmaceuticals Ltd, Napp Pharmaceuticals Group Ltd, Napp Laboratories Ltd, Bard Pharmaceuticals Ltd, and Qdem Pharmaceuticals Ltd. For this Plan, theses companies are collectively referred to as Napp Pharmaceuticals. 

Opioid Charter

For Mundipharma’s Charter on the responsible medical use of opioid analgesics in pain management click here.

Opioid Safety Statement

“Attention should be given as the use of opioids has a risk of addiction, misuse and abuse. Therefore, appropriate assessment and monitoring is a requirement at initiation, maintenance and tapering down of opioid therapy.”